Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Oct;105(10):1321-6.
doi: 10.1111/cas.12501. Epub 2014 Sep 29.

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

Takuji Okusaka  1 , Masafumi Ikeda, Akira Fukutomi, Tatsuya Ioka, Junji Furuse, Shinichi Ohkawa, Hiroyuki Isayama, Narikazu Boku
Affiliations
Clinical Trial

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

Takuji Okusaka et al. Cancer Sci. 2014 Oct.

Abstract

The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine the efficacy and safety of FOLFIRINOX in chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. FOLFIRINOX (i.v. infusion of 85 mg/m(2) oxaliplatin, 180 mg/m(2) irinotecan, and 200 mg/m(2) l-leucovorin, followed by a bolus of 400 mg/m(2) fluorouracil and a 46-h continuous infusion of 2400 mg/m(2) fluorouracil) was given every 2 weeks. The primary endpoint was the response rate. The 36 enrolled patients received a median of eight (range, 1-25) treatment cycles. The response rate was 38.9% (95% confidence interval [CI], 23.1-56.5); median overall survival, 10.7 months (95% CI, 6.9-13.2); and median progression-free survival, 5.6 months (95% CI, 3.0-7.8). Major grade 3 or 4 toxicities included neutropenia (77.8%), febrile neutropenia (22.2%), thrombocytopenia (11.1%), anemia (11.1%), anorexia (11.1%), diarrhea (8.3%), nausea (8.3%), elevated alanine aminotransferase levels (8.3%), and peripheral sensory neuropathy (5.6%). Febrile neutropenia occurred only during the first cycle. There were no treatment-related deaths. FOLFIRINOX can be a standard regimen showing favorable efficacy and acceptable toxicity profile in chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.

Keywords: Chemotherapy; FOLFIRINOX; irinotecan; oxaliplatin; pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier analysis of overall survival in a phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. The median survival was 10.7 months (95% confidence interval, 6.9–13.2). One-year overall survival was 41.5% (95% confidence interval, 25.4–56.8). Data on nine patients were censored.
Figure 2
Figure 2
Kaplan–Meier analysis of progression-free survival in a phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. The median progression-free survival was 5.6 months (95% confidence interval, 3.0–7.8). Data on eight patients were censored.
See this image and copyright information in PMC

Comment in

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Japanese Ministry of Health; Labour and Welfare. 2012. Statistical investigation result : [cited 27 November 2013] Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei12/index.html [In Japanese]
    1. Center for Cancer control and Information Services, Latest Cancer Statistics. [cited 21 November 2013] Available from URL: http://ganjoho.jp/public/statistics/pub/statistics01.html [In Japanese]
    1. Burris HA, III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13. - PubMed
    1. Moore MJ, Goldstein D, Hamm J, et al. Erlotnib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer instutite of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6. - PubMed

Publication types